After two years of lackluster performances, Celgene appeared to be on a roll in 2017.
After two years of lackluster performances, Celgene appeared to be on a roll in 2017. Then the bottom fell out.
In October, the big biotech stock gave up all of its year-to-date gains, and then some.
